Docetaxel D9
| Product Name | Docetaxel D9 |
|---|---|
| Alternate Names | Docetaxel Stable Isotopes, Stable Isotopes of Docetaxel |
| CAT No. | CS-O-06555 |
| CAS No. | 940867-25-4 |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 816.93 g/mol |
| Mol. For. | C₄₃H₄₄D₉NO₁₄ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Docetaxel |
| Purity | Not less than 90 % |
| Therapeutic | Anti-Cancer / Oncology |
| Smileys | CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O |
| Canonical Smiles | CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O |
| InchIKey | ZDZOTLJHXYCWBA-ZYSSTJHRSA-N |
| Inchl | InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1/i3D3,4D3,5D3 |
| IUPAC | [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-15-[(2R,3S)-3-[[1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-yl]oxycarbonylamino]-2-hydroxy-3-phenylpropanoyl]oxy-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Docetaxel D9 is a derivative of Docetaxel, a widely used chemotherapy drug that belongs to the class of taxane drugs. It is primarily used for the treatment of various types of cancer, including breast cancer, lung cancer, prostate cancer, and ovarian cancer, among others. Docetaxel D9 is a deuterated analog of Docetaxel, which means it contains a higher concentration of deuterium atoms, which are heavy isotopes of hydrogen. This modification enhances the stability, solubility, and pharmacokinetic properties of the drug, making it more potent and effective.
The mechanism of action of Docetaxel D9 involves binding to the microtubules in cancer cells, which prevents their normal function of cell division and proliferation. This leads to cell death and tumor regression. Docetaxel D9 is administered intravenously, and the dosage and duration of the treatment depend on the type and stage of cancer, as well as the patient's overall health status.
Chemically, Docetaxel D9 has a molecular formula of C43H53NO14D9 and a molecular weight of 845.06 g/mol. It is a white to pale yellow crystalline powder that is insoluble in water but soluble in ethanol and acetone. The drug has a half-life of approximately 11.1 hours, and it is metabolized in the liver and excreted in the bile and feces. The most common side effects of Docetaxel D9 include nausea, vomiting, hair loss, fatigue, and anemia, among others. However, these side effects are generally manageable and temporary, and they can be minimized with proper medical supervision and supportive care.
Get an Instant Quote
Related Compounds
Hexanoyl Docetaxel Metabolites M1 and M3-d6 (Mixture of Diastereomers) | Docetaxel-d6 Metabolites M1 and M3 (Mixture of Diastereomers) |